Literature DB >> 27668858

Safety and outcomes of preoperative embolization of intracranial hemangioblastomas: A systematic review.

Leonel Ampie1, Winward Choy1, Jonathan B Lamano1, Kartik Kesavabhotla1, Rajwant Kaur1, Andrew T Parsa1, Orin Bloch2.   

Abstract

INTRODUCTION: While preoperative embolization is often reserved for large and highly vascular tumors in order to minimize blood loss, its safety and efficacy in the treatment of hemangioblastomas (HB) is unclear. We present the largest systematic review focusing on the safety and outcome of preoperative embolization of intracranial HB.
MATERIALS AND METHODS: To identify all cases of preoperative embolization for HB, a literature search was conducted via Medline (OVID and PubMed), Scopus, Embase, and Web of Science. Studies that were in English, included intracranial hemangioblastomas treated with preoperative embolization and provided sufficient disaggregated clinical data for each patient were included. Historical control patients with non-embolized intracranial HB undergoing resection were similarly identified.
RESULTS: A total of 111 patients that underwent preoperative embolization of HB prior to planned resection were identified. Patient age ranged from 12 to 72 years, with a cohort of 63% males and 36% females. Nine studies comprising 392 non-embolized patients were included as controls. Gross total resection was achieved in 83.7% of embolized and 95.6% of non-embolized patients. Intraoperative blood transfusion was required in 15.3% of embolized and 0.51% of non-embolized controls, while rates of post-operative hemorrhage were 8.4% and 1.6%, respectively. Complication rates from embolization were 11.7% and following consequent surgery were 20.7%. DISCUSSION: Embolization did not increase rates of gross total resection, decrease estimated blood loss, or decrease incidence of complications. Not only does embolization fail to mitigate surgical risks, the embolization procedure itself carries significant risk for complications. Embolization should not be standard of care for intracranial HB.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Embolization; Hemangioblastoma; Intracranial; Surgery

Mesh:

Year:  2016        PMID: 27668858     DOI: 10.1016/j.clineuro.2016.09.008

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  7 in total

1.  Post-embolization neurological syndrome after embolization for intracranial and skull base tumors: transient exacerbation of neurological symptoms with inflammatory responses.

Authors:  Yujiro Tanaka; Takao Hashimoto; Daisuke Watanabe; Hirofumi Okada; Daichi Kato; Shigeru Aoyagi; Jiro Akimoto; Michihiro Kohno
Journal:  Neuroradiology       Date:  2018-06-18       Impact factor: 2.804

2.  Biological and clinical impact of central nervous system hemangioblastomas in Chinese patients with von Hippel-Lindau disease: implications for treatment.

Authors:  Liang Li; Zhiqiang Yi; Zhen Liu; Hongzhou Duan; Runchun Lu; Chunwei Li; Lei Li; Kan Gong
Journal:  Hered Cancer Clin Pract       Date:  2020-10-22       Impact factor: 2.857

3.  Solid vs. cystic predominance in posterior fossa hemangioblastomas: implications for cerebrovascular risks and patient outcome.

Authors:  Samuel Moscovici; Carlos Candanedo; Sergey Spektor; José E Cohen; Andrew H Kaye
Journal:  Acta Neurochir (Wien)       Date:  2021-04-03       Impact factor: 2.216

4.  A novel neuroimaging assessment of predictive risk factors associated with intraoperative massive hemorrhage in intracranial solid hemangioblastoma.

Authors:  Qiang Gao; Lan Zhang; Guoqing Wang; Dingkang Xu; Mengzhao Feng; Fang Wang; Qingjie Wei; Xianzhi Liu; Fuyou Guo
Journal:  Quant Imaging Med Surg       Date:  2019-11

5.  Intracranial hemangioblastoma - A SEER-based analysis 2004-2013.

Authors:  Ha Son Nguyen; Ninh B Doan; Michael Gelsomino; Saman Shabani; Ahmed J Awad; Mayank Kaushal; Martin M Mortazavi
Journal:  Oncotarget       Date:  2018-06-15

6.  Treatment Outcome of Intracranial Tumor Embolization in Japan: Japanese Registry of NeuroEndovascular Therapy 3 (JR-NET3).

Authors:  Kenji Sugiu; Tomohito Hishikawa; Satoshi Murai; Yu Takahashi; Naoya Kidani; Shingo Nishihiro; Masafumi Hiramatsu; Isao Date; Tetsu Satow; Koji Iihara; Nobuyuki Sakai
Journal:  Neurol Med Chir (Tokyo)       Date:  2019-01-26       Impact factor: 1.742

7.  The usefulness of indocyanine green during surgery for hypervascular posterior fossa tumors.

Authors:  Takahiro Shinya; Hideki Nagamine; Ken-Ichi Sugawara; Shogo Ishiuchi
Journal:  Surg Neurol Int       Date:  2018-04-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.